By: Staff Reporter From: precisiononcologynews.com Tyme Technologies said on Monday it has dosed the first patient in its Phase II OASIS trial of SM-88 in previously treated metastatic hormone receptor (HR)-positive HER2-negative breast cancer patients. The investigator-initiated study at Georgetown University will initially enroll 30 patients with metastatic HR-positive HER2-negative breast cancer who have previously received at least two lines …
-
-
My Personal Breast Cancer Awareness Purpose
-
Breast Cancer Awareness – Our Breast Cancer Helpers Need Help, Too
-
What Do We Know about the Breast Cancer Pink Ribbon
-
A World Turned Upside Down
-
About Joining a Private Breast Cancer Online Support Group
